PROM1 and colorectal carcinoma: Notably, among patients with stage III CRC, those with CD133-positive CTCs had a significantly lower 5-year DSS rate compared to CD133-negative cases (73.8% vs. 96.3%, p = 0.021; Figure S1d), suggesting a prognostic role of CD133 expression in this subgroup.